InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,612.47
(
-0.38%
)
US TECH 100
19,957.20
(
-0.80%
)
Dow Jones
39,788.13
(
0.17%
)
Brent Oil
85.09
(
0.05%
)
Bitcoin
57,758.41
(
0.00%
)
Post# of 252564
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: caravon post# 157869

Wednesday, 03/06/2013 10:50:53 PM

Wednesday, March 06, 2013 10:50:53 PM

Post# of 252564

He did not say anything new.

Simply not true. CEO, while not going into specifics, said he believes the FGFR inhibitor has some angle to make it more competitive to others in the clinic. He also disclosed that ARQL has two pre-clinical programs targeting BTK inhibitors and a "more novel" S6K inhibitor. (Never heard of the latter before.)
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up